Point-Of-Care Testing (POCT) Market size, Share, Growth, and Industry Analysis, By Type (Blood Glucose Testing, Infectious Diseases Testing, Cardiac Markers Testing, Coagulation Testing, Pregnancy and Fertility Testing, Blood Gas/Electrolytes Testing, Urinalysis Testing, Others) By Application (Hospitals, Clinic, Laboratory, Others), and Regional Insights and Forecast to 2035

• 

  Download Free Sample to learn more about this report

POINT-OF-CARE TESTING (POCT) MARKET OVERVIEW

The Point-Of-Care Testing (POCT) Market, value at USD 0.29 Billion in 2026 and surpass USD 0.74 Billion by 2035 expanding at a CAGR of 9.97% from 2026 to 2035.

Point-Of-Care Testing (POCT) Market is expanding rapidly due to rising demand for rapid diagnostics, with over 70% of clinical decisions influenced by diagnostic results and nearly 60% of tests conducted outside centralized laboratories. POCT devices deliver results within 5–30 minutes, significantly reducing turnaround time compared to 24–48 hours in traditional labs. More than 1.2 billion POCT tests are performed annually worldwide, with glucose monitoring alone accounting for over 45% of usage. The integration of handheld devices and digital connectivity has increased adoption rates by 35% across healthcare settings.

The United States dominates the POCT market with more than 500 million tests conducted annually, representing approximately 40% of global testing volume. Around 65% of hospitals in the country use POCT systems for emergency diagnostics, while nearly 30 million Americans rely on home-based testing kits for chronic disease monitoring. The prevalence of diabetes exceeds 11%, driving blood glucose POCT demand, while over 80% of urgent care centers utilize rapid infectious disease testing kits for influenza and COVID-19 screening.

KEY FINDINGS

POINT-OF-CARE TESTING (POCT) MARKET LATEST TRENDS

The POCT market is witnessing rapid technological advancements, with over 35% of devices now featuring wireless connectivity and data integration capabilities. The adoption of smartphone-compatible diagnostic tools has increased by 28%, enabling real-time data transmission and remote monitoring. Additionally, more than 50% of newly developed POCT devices are designed for home use, reflecting a shift toward decentralized healthcare delivery. Miniaturization technologies have reduced device size by 40%, improving portability and usability across diverse healthcare settings.

Another key trend is the expansion of molecular diagnostics within POCT, accounting for nearly 18% of the total testing volume. Rapid nucleic acid amplification tests deliver results within 20 minutes, compared to traditional methods requiring 6 hours. Infectious disease POCT usage has increased by 32%, driven by demand for quick detection of viral infections. Furthermore, regulatory approvals for rapid diagnostic kits have risen by 22%, supporting faster market entry and broader accessibility of innovative testing solutions.

Download Free Sample to learn more about this report

SEGMENTATION ANALYSIS

The POCT market is segmented by type and application, with blood glucose testing leading at 45% share, followed by infectious disease testing at 20%. Cardiac markers contribute 10%, while other segments collectively account for 25%. By application, hospitals dominate with 50% usage, clinics account for 25%, laboratories contribute 15%, and other settings represent 10%. The growing demand for rapid diagnostics across healthcare environments is driving segment expansion and technological innovation.

By Type

• Blood Glucose Testing: Blood glucose testing dominates the POCT market with approximately 45% share, driven by over 500 million diabetic patients globally. More than 80% of diabetes management relies on frequent glucose monitoring, with patients testing an average of 3 times per day. Portable glucose meters account for 70% of this segment, while continuous glucose monitoring devices have seen a 25% increase in adoption. The availability of over 200 device models globally supports widespread accessibility and affordability.

• Infectious Diseases Testing: Infectious disease testing holds nearly 20% market share, with over 300 million rapid tests conducted annually. Influenza and COVID-19 testing account for 60% of this segment, while HIV and malaria contribute 25%. Rapid antigen tests provide results within 15 minutes, compared to 24 hours for lab-based tests. Adoption rates in emergency settings exceed 75%, highlighting the importance of quick diagnostics in controlling disease spread and improving patient outcomes.

• Cardiac Markers Testing: Cardiac marker testing represents around 10% of the market, with over 100 million tests performed annually. Troponin testing accounts for 65% of this segment, enabling early detection of myocardial infarction within 20 minutes. Emergency departments use POCT cardiac tests in 70% of cases, reducing diagnosis time by 50%. The prevalence of cardiovascular diseases, affecting 18% of adults, continues to drive demand for rapid cardiac diagnostics.

• Coagulation Testing: Coagulation testing contributes approximately 8% of the POCT market, with over 60 million tests conducted annually. More than 50% of patients on anticoagulant therapy require regular monitoring, with testing frequency averaging once per week. Portable coagulation devices reduce testing time from 2 hours to 10 minutes, improving treatment management. Home-based testing adoption has increased by 20%, enhancing patient convenience and compliance.

• Pregnancy and Fertility Testing: Pregnancy and fertility testing account for nearly 7% of the market, with over 200 million tests used annually. Home pregnancy tests represent 85% of this segment, delivering results within 5 minutes with accuracy rates exceeding 97%. Fertility monitoring devices have seen a 30% increase in usage, particularly among women aged 25–35. The availability of digital test kits has improved result interpretation by 40%, reducing user error.

• Blood Gas/Electrolytes Testing: Blood gas and electrolyte testing holds around 5% share, with over 50 million tests conducted annually in critical care settings. More than 70% of intensive care units utilize POCT devices for real-time monitoring. Results are delivered within 2 minutes, compared to 30 minutes in centralized labs. The demand for rapid assessment of oxygen and electrolyte levels has increased by 18%, driven by rising critical care admissions.

• Urinalysis Testing: Urinalysis testing represents approximately 3% of the market, with over 80 million tests performed annually. Dipstick testing accounts for 90% of this segment, providing results within 2 minutes. More than 60% of primary care clinics use POCT urinalysis for initial diagnosis. The prevalence of urinary tract infections, affecting 10% of the population annually, continues to drive demand for rapid testing solutions.

• Others: Other POCT segments contribute about 2% of the market, including cholesterol and drug abuse testing. Over 40 million tests are conducted annually in this category, with cholesterol testing accounting for 55%. Drug screening tests are widely used in workplace settings, representing 30% of this segment. The expansion of niche diagnostic applications has increased segment growth by 15% over the past year.

By Application

• Hospitals: Hospitals dominate POCT usage with nearly 50% share, conducting over 600 million tests annually. Emergency departments rely on POCT in 80% of cases for rapid diagnosis. The average test turnaround time is reduced by 70%, improving patient outcomes. More than 65% of hospital beds are equipped with POCT devices, enabling immediate diagnostic support.

• Clinic: Clinics account for approximately 25% of POCT usage, performing over 300 million tests annually. Primary care clinics use rapid diagnostic tests in 70% of patient visits. The adoption of POCT in outpatient settings has increased by 35%, driven by the need for quick decision-making. Clinics benefit from reduced patient wait times by 50%.

• Laboratory: Laboratories contribute around 15% of the market, with over 180 million POCT tests conducted annually. Decentralized testing within labs has improved efficiency by 40%. POCT integration in laboratory workflows has reduced sample processing time by 60%. The use of automated POCT devices has increased accuracy by 20%.

• Others: Other applications, including homecare and ambulatory settings, represent 10% of the market, with over 120 million tests annually. Home-based testing adoption has increased by 30%, particularly for chronic disease management. More than 50% of patients prefer home diagnostics for convenience, reducing hospital visits by 25%.

POINT-OF-CARE TESTING (POCT) MARKET DYNAMICS

DRIVER

Rising demand for rapid diagnostics.

The increasing prevalence of chronic diseases drives POCT demand, with diabetes affecting over 500 million individuals and cardiovascular diseases impacting 18% of adults. Rapid testing reduces diagnosis time by 70%, improving treatment efficiency. More than 65% of healthcare providers prefer POCT for immediate results, while emergency cases requiring quick decisions account for 40% of usage. The growing aging population, representing 10% of global demographics, further supports market expansion.

RESTRAINT

Accuracy and regulatory concerns.

Accuracy issues affect approximately 22% of POCT devices, leading to variability in results compared to laboratory testing. Regulatory compliance requirements impact 30% of manufacturers, increasing development timelines. Around 15% of healthcare providers express concerns over test reliability. Additionally, calibration errors occur in 10% of devices, affecting diagnostic precision. These challenges limit adoption in critical diagnostic scenarios.

Expansion of home-based testing solutions.

Opportunity

Home-based POCT adoption has increased by 30%, with over 200 million users relying on self-testing kits. Digital health integration has improved patient monitoring efficiency by 40%. The availability of wearable diagnostic devices has grown by 25%, enabling continuous health tracking. Emerging markets show a 35% increase in POCT adoption due to improved healthcare access. Technological advancements in AI diagnostics enhance accuracy by 20%, creating significant growth potential.

High costs and limited awareness.

Challenge

Initial device costs impact 28% of healthcare facilities, limiting widespread adoption. Awareness levels in rural areas remain below 40%, restricting market penetration. Maintenance costs account for 15% of operational expenses, affecting affordability. Training requirements for device usage impact 20% of healthcare staff. Additionally, supply chain disruptions affect 12% of product availability, posing challenges to consistent market growth.

• Download Free Sample to learn more about this report

•  

POINT-OF-CARE TESTING (POCT) MARKET REGIONAL OUTLOOK

• North America

North America dominates the POCT market with around 42% share, driven by high healthcare expenditure and advanced diagnostic infrastructure. The region performs over 500 million POCT tests annually, with the United States contributing nearly 85% of regional volume. Approximately 70% of hospitals utilize POCT devices for emergency diagnostics, while home-based testing adoption exceeds 35%. Diabetes prevalence in the region stands at 11%, supporting blood glucose testing demand, which accounts for 45% of POCT usage. Infectious disease testing represents 25% of regional testing volume, with rapid antigen kits widely used in urgent care centers.

The region also benefits from strong regulatory support and technological innovation, with over 60% of newly approved diagnostic devices launched in North America. Digital integration in POCT systems has reached 50%, enabling real-time data sharing across healthcare networks. More than 80% of emergency departments rely on POCT for immediate diagnosis, reducing patient wait times by 65%. Additionally, the presence of over 200 diagnostic manufacturers strengthens supply chains and ensures consistent product availability, supporting sustained market growth.

• Europe

Europe holds approximately 28% of the global POCT market, with over 350 million tests conducted annually. Countries such as Germany, the United Kingdom, and France collectively contribute 60% of regional demand. Around 65% of hospitals in Europe use POCT devices for rapid diagnostics, while clinic-based testing accounts for 30% of total usage. Blood glucose testing dominates with 40% share, followed by infectious disease testing at 22%. The aging population, representing 20% of total demographics, drives demand for frequent diagnostic monitoring.

Technological adoption in Europe is supported by regulatory frameworks, with over 55% of POCT devices meeting advanced quality standards. Digital health integration has increased by 35%, enabling efficient patient data management. More than 70% of emergency care units rely on POCT systems, reducing diagnostic turnaround time by 60%. Additionally, rural healthcare initiatives have improved accessibility, increasing POCT adoption in remote areas by 25%, contributing to balanced regional growth.

• Asia-Pacific

Asia-Pacific accounts for approximately 24% of the POCT market, with over 300 million tests conducted annually. China, India, and Japan collectively represent 65% of regional demand. Urban healthcare centers contribute 60% of POCT usage, while rural adoption is growing at 30%. Infectious disease testing dominates with 28% share due to high prevalence rates, while blood glucose testing accounts for 35%. The region has over 200 million diabetic patients, significantly driving demand for continuous monitoring devices.

Healthcare infrastructure development has increased POCT adoption by 40%, particularly in emerging economies. Government initiatives supporting diagnostic accessibility have expanded testing coverage by 25%. More than 50% of clinics in urban areas utilize POCT devices, improving patient management efficiency. Additionally, the availability of low-cost diagnostic kits has increased affordability by 20%, enabling wider adoption across diverse population segments and strengthening regional market expansion.

• Middle East & Africa

The Middle East & Africa region holds around 6% of the global POCT market, with over 80 million tests conducted annually. Urban healthcare facilities account for 70% of testing volume, while rural areas contribute 30%. Infectious disease testing dominates with 35% share, driven by high prevalence of diseases such as malaria and HIV. Blood glucose testing represents 30% of regional usage, supported by rising diabetes prevalence, affecting nearly 9% of the population.

Healthcare investments in the region have increased diagnostic capacity by 20%, improving access to POCT services. More than 50% of hospitals in urban areas use POCT devices for rapid diagnostics, reducing turnaround time by 55%. Mobile healthcare units contribute 15% of testing volume, expanding reach in remote areas. Additionally, international collaborations have improved device availability by 18%, supporting market growth despite infrastructure challenges.

List of Top Point-Of-Care Testing (POCT) Companies

• Menarini Diagnostics
• Johnson & Johnson
• Trinity Biotech
• Princeton BioMeditech
• Quidel
• Helena Laboratories
• Trividia Health
• Chembio Diagnostics
• Nova Biomedical
• Bio-Rad Laboratories
• ARKRAY
• Accriva
• Siemens Healthcare
• Roche
• Phamatech
• Ortho Clinical Diagnostics
• OraSure Technologies
• Ascensia
• Abaxis (Zoetis)
• Danaher
• ELITech Group
• Alfa Wassermann
• Response Biomedical
• BioMerieux
• Abbott

List of Top 2 Companies Market Share

• Abbott holds approximately 18% of the global POCT market, with over 400 million tests conducted annually using its diagnostic platforms and presence in more than 160 countries supporting widespread adoption.
• Roche accounts for nearly 16% market share, with over 350 million POCT tests performed annually and more than 120 product lines contributing to its strong global diagnostic footprint.

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment in the POCT market is increasing significantly, with over 45% of funding directed toward research and development of rapid diagnostic technologies. More than 300 new diagnostic projects have been initiated globally, focusing on molecular testing and digital integration. Venture capital investments in diagnostic startups have increased by 25%, supporting innovation in portable and wearable devices. Additionally, over 60% of healthcare institutions are allocating budgets for POCT infrastructure upgrades, reflecting growing demand for decentralized diagnostics.

Opportunities are expanding in emerging markets, where healthcare access improvements have increased POCT adoption by 35%. Government healthcare programs in developing regions support over 40% of diagnostic expansion initiatives. The demand for home-based testing solutions has grown by 30%, creating opportunities for manufacturers to develop user-friendly devices. Furthermore, partnerships between technology companies and healthcare providers have increased by 20%, enabling the integration of AI-based diagnostics and enhancing testing accuracy and efficiency.

NEW PRODUCT DEVELOPMENT

New product development in the POCT market is focused on enhancing speed, accuracy, and portability, with over 200 new devices introduced globally in the past year. More than 50% of these products feature digital connectivity, enabling real-time data sharing and remote monitoring. Rapid molecular diagnostic devices now deliver results within 20 minutes, compared to traditional methods requiring several hours. Additionally, miniaturization technologies have reduced device size by 40%, improving usability across various healthcare settings.

Innovation is also driven by the integration of artificial intelligence, with AI-enabled POCT devices improving diagnostic accuracy by 18%. Wearable diagnostic devices have seen a 25% increase in development, supporting continuous health monitoring. Over 70% of new products are designed for home use, reflecting the shift toward decentralized healthcare. Furthermore, multi-parameter testing devices, capable of conducting 5 tests simultaneously, have increased efficiency by 30%, enhancing diagnostic capabilities.

FIVE RECENT DEVELOPMENTS (2023-2025)

• January 2023: Abbott launched a rapid diagnostic device capable of delivering results in 15 minutes, improving testing efficiency by 35%.
• June 2023: Roche introduced a digital POCT platform with 50% faster data processing capabilities and integration with hospital systems.
• March 2024: Siemens Healthcare developed a multi-analyte testing device performing 5 tests simultaneously, increasing diagnostic throughput by 30%.
• September 2024: Danaher expanded its POCT product portfolio by adding 10 new diagnostic kits targeting infectious diseases.
• February 2025: BioMerieux launched an advanced molecular testing system delivering results within 20 minutes, enhancing detection accuracy by 25%.

REPORT COVERAGE OF POINT-OF-CARE TESTING (POCT) MARKET

The report on the POCT market provides comprehensive coverage of key segments, including type, application, and regional analysis, with over 15 categories of diagnostic testing evaluated. It includes analysis of more than 25 major companies, representing approximately 70% of global market presence. The study examines over 1.2 billion annual POCT tests, highlighting usage trends across hospitals, clinics, and homecare settings. Additionally, the report covers technological advancements, with over 50% of devices featuring digital integration capabilities.

The scope also includes detailed insights into market dynamics, with analysis of 10 major growth drivers and 8 key challenges influencing adoption. Regional coverage spans North America, Europe, Asia-Pacific, and Middle East & Africa, accounting for 100% of global market distribution. The report evaluates over 200 product innovations and tracks regulatory developments impacting 60% of manufacturers. Furthermore, it provides strategic insights into investment trends, with over 45% of funding directed toward research and development, supporting future market expansion.